Skip to content
10-Q

Quarterly Report

Damora Therapeutics, Inc. DMRA

0000950170-24-119809

← back to feed
Filed
Nov 1, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 30, 2024 1.32M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $19.68M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $21.47M
Current Liabilities Q3 2024 · Sep 30, 2024 $2.44M
Current Liabilities Q3 2024 · Dec 31, 2023 $5.83M
Total Liabilities Q3 2024 · Sep 30, 2024 $2.44M
Total Liabilities Q3 2024 · Dec 31, 2023 $5.9M
Current Assets Q3 2024 · Sep 30, 2024 $21.18M
Current Assets Q3 2024 · Dec 31, 2023 $36.77M
Total Assets Q3 2024 · Sep 30, 2024 $23.38M
Total Assets Q3 2024 · Dec 31, 2023 $38.23M
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.08M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 1.06M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$25.44M
Stockholders Equity Q3 2024 · Sep 30, 2023 $37.38M
Stockholders Equity Q3 2024 · Jun 30, 2023 $43.7M
Stockholders Equity Q3 2024 · Dec 31, 2022 $61.75M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$7.50
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$30.19
Eps Basic restated Q3 2024 · Sep 30, 2023 −$7.50
Eps Basic restated Q3 2024 · Sep 30, 2023 −$30.19
Sga Expense Q3 2024 · Sep 30, 2023 $3.3M
Sga Expense Q3 2024 · Sep 30, 2023 $9.5M
Rd Expense Q3 2024 · Sep 30, 2023 $2.55M
Rd Expense Q3 2024 · Sep 30, 2023 $21M
Net Income Q3 2024 · Sep 30, 2023 −$8.14M
Net Income Q3 2024 · Sep 30, 2023 −$31.87M
Operating Income Q3 2024 · Sep 30, 2023 −$8.58M
Operating Income Q3 2024 · Sep 30, 2023 −$33.23M